Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Latanoprostene Bunod

FDA-approved product (solution/drops, ophthalmic), marketed as Latanoprostene Bunod, Vyzulta.

Registered studies
9
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Latanoprostene Bunod
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Latanoprostene Bunod in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Latanoprostene Bunod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

    NCT04140279 · start 2022-05-13

    Registered record
    Registry ID
    NCT04140279
    Conditions
    Ocular Hypertension
    Interventions
    Latanoprostene Bunod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2022-05-13
    Completion
    2023-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension
    InterventionLatanoprostene Bunod; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Nailfold Capillary Blood Flow With Latanoprost Bunod

    NCT03949244 · start 2019-08-15

    Registered record
    Registry ID
    NCT03949244
    Conditions
    Glaucoma, Open-Angle
    Interventions
    Latanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-08-15
    Completion
    2020-10-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle
    InterventionLatanoprost 0.005%; Latanoprost bunod 0.024%; Normal saline 0.9%; Nailfold capillaroscopy
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

    NCT03931317 · start 2018-12-03

    Registered record
    Registry ID
    NCT03931317
    Conditions
    OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
    Interventions
    Latanoprostene bunod 0.024% QD; Timolol maleate 0.5% BID
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-12-03
    Completion
    2023-03-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
    InterventionLatanoprostene bunod 0.024% QD; Timolol maleate 0.5% BID
    PhaseNot applicable
    Registry statusCompleted

  • Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

    NCT01895972 · start 2013-07-05

    Registered record
    Registry ID
    NCT01895972
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Latanoprostene bunod
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07-05
    Completion
    2015-04-14
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionLatanoprostene bunod
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

    NCT01895985 · start 2013-07

    Registered record
    Registry ID
    NCT01895985
    Conditions
    Intraocular Pressure
    Interventions
    Latanoprostene bunod
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2013-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Pressure
    InterventionLatanoprostene bunod
    PhasePhase 1
    Registry statusCompleted

  • Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

    NCT01749904 · start 2013-01-31

    Registered record
    Registry ID
    NCT01749904
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    BOL-303259-X; Timolol; BOL-303259-X
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01-31
    Completion
    2015-09-30
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBOL-303259-X; Timolol; BOL-303259-X
    PhasePhase 3
    Registry statusCompleted

  • Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

    NCT01749930 · start 2013-01

    Registered record
    Registry ID
    NCT01749930
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    BOL-303259-X; Timolol; BOL-303259-X
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2015-05
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBOL-303259-X; Timolol; BOL-303259-X
    PhasePhase 3
    Registry statusCompleted

  • BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

    NCT01707381 · start 2012-11

    Registered record
    Registry ID
    NCT01707381
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    BOL-303259-X; Timolol maleate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-02
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    InterventionBOL-303259-X; Timolol maleate
    PhasePhase 2
    Registry statusCompleted

  • Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

    NCT01223378 · start 2010-12-13

    Registered record
    Registry ID
    NCT01223378
    Conditions
    Intraocular Pressure
    Interventions
    BOL-303259-X; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12-13
    Completion
    2012-06-22
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Pressure
    InterventionBOL-303259-X; Latanoprost
    PhasePhase 2
    Registry statusCompleted